Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject was age 18 or older and in good health (Investigator discretion) with a recent stable medical history.~* Subjects who met the requirements from previous adalimumab psoriasis study participation.~Exclusion Criteria:~* Subject considered by the Investigator, for any reason, to be an unsuitable candidate for the study.~* Female subject who was pregnant or breast-feeding or considering becoming pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adalimumab (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).